Cruentaren, a new antifungal salicylate-type macrolide from Byssovorax cruenta (myxobacteria) with inhibitory effect on mitochondrial ATPase activity. Fermentation and biological properties

J Antibiot (Tokyo). 2006 Oct;59(10):664-8. doi: 10.1038/ja.2006.89.

Abstract

The novel macrolide cruentaren A was produced at levels up to 3.2 mg/liter by cultures of the myxobacterium Byssovorax cruenta. The new compound strongly inhibited the growth of yeasts and filamentous fungi and showed high cytotoxicity against L929 mouse fibroblast cells. A minor co-metabolite of cruentaren A, named cruentaren B, and identified as a six-membered lactone isomer of cruentaren A, showed only marginal cytotoxicity and no antifungal activity. Cruentaren A inhibited F0F1 mitochondrial ATP-hydrolysis in submitochondrial particles of yeasts and beef heart.

MeSH terms

  • Animals
  • Antifungal Agents / chemistry
  • Antifungal Agents / isolation & purification
  • Antifungal Agents / metabolism
  • Antifungal Agents / pharmacology*
  • Cattle
  • Fermentation
  • Fibroblasts
  • Fungi / drug effects
  • Isocoumarins / chemistry
  • Isocoumarins / isolation & purification
  • Isocoumarins / metabolism
  • Isocoumarins / pharmacology*
  • Macrolides / chemistry
  • Macrolides / isolation & purification
  • Macrolides / metabolism
  • Macrolides / pharmacology*
  • Mice
  • Mitochondria / drug effects
  • Mitochondria / enzymology
  • Mitochondrial Proton-Translocating ATPases / antagonists & inhibitors*
  • Molecular Structure

Substances

  • Antifungal Agents
  • Isocoumarins
  • Macrolides
  • cruentaren A
  • cruentaren B
  • Mitochondrial Proton-Translocating ATPases